Treatment of discogenic back pain with autologous bone marrow concentrate injection with minimum two year follow-up

摘要: The purpose of this study is to assess safety and feasibility intradiscal bone marrow concentrate (BMC) injections treat discogenic pain as an alternative surgery. A total 26 patients (11 male, 15 female, aged 18–61 years, 13 single level, two level) that met inclusion criteria chronic (> 6 months) low back pain, degenerative disc pathology assessed by magnetic resonance imaging (MRI) with modified Pfirrmann grade IV–VII at one or levels, candidate for surgical intervention (failed conservative treatment radiologic findings) a visual analogue scale (VAS) score 40 mm more initial visit. Initial Oswestry Disability Index (ODI) VAS average was 56.5 % 80.1 (0–100), respectively. Adverse event reporting, ODI score, MRI radiographic changes, progression surgery cellular analysis BMC were noted. Retrospective cell flow cytometry colony forming unit-fibroblast (CFU-F) assays performed characterise each patient’s compare clinical outcomes. injected into the nucleus pulposus symptomatic disc(s) under fluoroscopic guidance. Patients evaluated clinically prior three, six, 12 24 months radiographically months. There no complications from percutaneous aspiration injection. Of patients, (92 %) avoided through months, while 21 (81 years. surviving scores reduced 19.9 27.0 three sustained 18.3 22.9 respectively (p ≤ 0.001). Twenty had follow-up whom eight improved least grade, none discs worsened. Total rate reduction linked mesenchymal stem concentration Only five elected undergo (fusion artificial replacement) year milestone. This provides evidence in non-surgical autologous BMC, durable relief (71 reduction) improvements (> 64